Analysts Set Simulations Plus, Inc. (NASDAQ:SLP) Target Price at $51.40

Simulations Plus, Inc. (NASDAQ:SLP) has received an average recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $51.40.

A number of research analysts recently commented on SLP shares. Stephens began coverage on Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target for the company. BTIG Research dropped their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th.

Simulations Plus Trading Down 3.1 %

Shares of SLP opened at $30.93 on Friday. Simulations Plus has a 12 month low of $27.07 and a 12 month high of $51.22. The firm’s 50 day moving average is $30.80 and its 200-day moving average is $36.33. The stock has a market capitalization of $620.67 million, a PE ratio of 63.12 and a beta of 0.76.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $18.70 million for the quarter, compared to analyst estimates of $19.73 million. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The company’s revenue was up 19.9% on a year-over-year basis. During the same quarter last year, the company earned $0.18 EPS. Equities research analysts predict that Simulations Plus will post 1.1 earnings per share for the current fiscal year.

Insider Activity at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $27.66, for a total transaction of $553,200.00. Following the sale, the director now directly owns 3,462,584 shares of the company’s stock, valued at approximately $95,775,073.44. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 60,750 shares of company stock valued at $1,837,255 in the last quarter. Insiders own 20.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C bought a new stake in Simulations Plus during the 2nd quarter worth approximately $811,000. BNP Paribas Financial Markets lifted its holdings in shares of Simulations Plus by 402.9% during the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock worth $1,279,000 after purchasing an additional 32,002 shares during the period. Royce & Associates LP grew its stake in shares of Simulations Plus by 28.8% in the third quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock worth $7,602,000 after purchasing an additional 53,092 shares during the last quarter. US Bancorp DE increased its holdings in Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock valued at $159,000 after purchasing an additional 1,343 shares during the period. Finally, Quantbot Technologies LP bought a new position in Simulations Plus during the 3rd quarter worth $59,000. Institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.